Last reviewed · How we verify
ARA 290
ARA 290 is a peptide that acts as a glucagon receptor antagonist.
ARA 290 is a peptide that acts as a glucagon receptor antagonist. Used for Type 2 diabetes.
At a glance
| Generic name | ARA 290 |
|---|---|
| Also known as | pHSBP, Cibinetide |
| Sponsor | Claes-Göran Östenson |
| Drug class | Glucagon receptor antagonist |
| Target | Glucagon receptor |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By blocking glucagon receptors, ARA 290 aims to reduce glucose production in the liver, thereby lowering blood glucose levels. This mechanism is particularly relevant for the treatment of type 2 diabetes. ARA 290's glucagon receptor antagonism is thought to be a key factor in its therapeutic effects.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Vomiting
- Abdominal pain
Key clinical trials
- Cross-cultural Adaptation and Validity of the Arabic-translated NEUROPATHY-SPECIFIC QUALITY OF LIFE Questionnaire
- The Use of ARA290 for the Treatment of Diabetic Macular Oedema (PHASE2)
- Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis (PHASE2)
- ARA290 in T2D (Effects of ARA 290, an Erythropoietin Analogue) in Prediabetes and Type 2 Diabetes) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ARA 290 CI brief — competitive landscape report
- ARA 290 updates RSS · CI watch RSS
- Claes-Göran Östenson portfolio CI